al., 2008), and a similar effect was obtained with the beta-adrenergic antagonist propranolol (Gilpin and Koob, 2010). Given this preclinical and clinical evidence, there is active interest in the potential for drugs targeting central adrenergic receptors in the treatment of alcohol use disorders and the high prevalence of its comorbidity with stress-related illnesses such as PTSD (Kenna et al., 2016; Simpson et al., 2015).
